A. Vergnenègre

发表

[The costs of asthma in France: an economic analysis by a Markov model].

V. Vandewalle, C. Chouaid, A. Vergnenègre, 2004, Revue des maladies respiratoires.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

E. Felip, F. de Marinis, G. Altavilla, 2012, The Lancet. Oncology.

Hospital admissions related to acute exacerbations of chronic obstructive pulmonary disease in France, 1998-2007.

N. Roche, M. Zureik, C. Chouaid, 2011, Respiratory medicine.

Management of malignant pleural mesothelioma: a French multicenter retrospective study (GFPC 0802 study)

J. Mazières, C. Chouaid, A. Vergnenègre, 2015, BMC Cancer.

Economic analyses of immune-checkpoint inhibitors to treat lung cancer

C. Chouaid, A. Vergnenègre, 2020, Expert review of pharmacoeconomics & outcomes research.

Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer.

K. Syrigos, K. O'Byrne, Keunchil Park, 2019, The New England journal of medicine.

[Efficacy of docetaxel in non-small cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology].

A. Vergnenègre, H. Léna, G. Robinet, 2000, Revue des maladies respiratoires.

Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial.

E. Felip, F. de Marinis, M. Taron, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Quality of medical records in the "Medical Information System Program": application of the lot quality assurance sampling method].

R. Salamon, M. Druet‐Cabanac, P. Preux, 2002, Revue d'epidemiologie et de sante publique.

Chronic bronchitis among French adults: high prevalence and underdiagnosis

N. Roche, P. Preux, F. Neukirch, 2002, European Respiratory Journal.

Second-line treatments of small-cell lung cancers

G. Quéré, C. Chouaid, A. Vergnenègre, 2017, Expert review of anticancer therapy.

Updated Overall Survival Analysis From IMpower110: Atezolizumab versus Platinum-Based Chemotherapy in Treatment-Naive PD-L1-Selected Non-Small Cell Lung Cancer.

G. Giaccone, R. Herbst, E. Felip, 2021, Journal of Thoracic Oncology.

First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers

K. Chouahnia, A. Vergnenègre, G. des Guetz, 2019, Journal of Cancer Research and Clinical Oncology.

Impact of chronic airflow obstruction in a working population

N. Roche, T. Perez, F. Neukirch, 2008, European Respiratory Journal.

Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3)

C. Mermel, E. Felip, J. Bosch-Barrera, 2012 .

Chronic bronchitis in the general population: influence of age, gender and socio-economic conditions.

N. Roche, M. Zureik, A. Ferré, 2012, Respiratory medicine.

A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.

P. Auquier, J. Pujol, F. Barlesi, 2015, Interactive cardiovascular and thoracic surgery.

[The Lady Windermere syndrome: clinical and bacteriological data and progress in seven cases].

A. Vergnenègre, B. Melloni, P. Abdo, 2012, Revue des maladies respiratoires.

Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.

B. Milleron, F. Barlesi, C. Chouaid, 2010 .

Cost-Effectiveness of Second-Line Chemotherapy for Non-small Cell Lung Cancer: An Economic, Randomized, Prospective, Multicenter Phase III Trial Comparing Docetaxel and Pemetrexed: The GFPC 05-06 Study

C. Chouaid, A. Vergnenègre, R. Corre, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

FEV1/FVC and FEV1 for the assessment of chronic airflow obstruction in prevalence studies: do prediction equations need revision?

N. Roche, T. Perez, F. Neukirch, 2008, Respiratory medicine.

[A phase II study of weekly cisplatine plus oral vinorelbine with concomittant radiotherapy in non-dependent elderly patients with localized inoperable non small cell lung carcinoma (Essai GFPC 08-06, Raccosa)].

A. Vergnenègre, B. Marín, C. Locher, 2011, Revue des maladies respiratoires.

Randomized multicentric phase II study of carboplatin/gemcitabine and cisplatin/vinorelbine in advanced non-small cell lung cancer GFPC 99-01 study (Groupe français de pneumo-cancérologie).

P. Fournel, A. Vergnenègre, H. Léna, 2006, Lung cancer.

Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial.

C. Robert, G. Deplanque, O. Chosidow, 2016, Journal of the American Academy of Dermatology.

A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study).

C. Chouaid, A. Vergnenègre, R. Corre, 2012, Lung cancer.

An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer

U. Siebert, S. Walzer, C. Chouaid, 2011, Current medical research and opinion.

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer

M. Rugge, R. Rosell, M. Taron, 2016, BMC Cancer.

Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer.

U. Siebert, S. Walzer, J. de Castro Carpeno, 2010, Lung cancer.

[Radon and domestic exposure].

A. Vergnenègre, B. Melloni, F. Bonnaud, 2000, Revue des maladies respiratoires.

How many drugs in the maintenance setting for non-small-cell lung cancer? For what benefit?

A. Vergnenègre, 2013, Annals of palliative medicine.

Treatment of lung cancer: will financial issues become a criterion of choice?

C. Chouaid, A. Vergnenègre, I. Borget, 2013, Expert review of pharmacoeconomics & outcomes research.

Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.

E. Felip, F. de Marinis, L. Paz-Ares, 2015, JAMA oncology.

EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.

E. Felip, R. Rosell, M. Taron, 2012 .

Cost‐Effectiveness Analysis of Afatinib versus Gefitinib for First‐Line Treatment of Advanced EGFR‐Mutated Advanced Non–Small Cell Lung Cancers

G. de Pouvourville, D. Moro-Sibilot, C. Chouaid, 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Multicenter observational study of erlotinib therapy (OBSTAR) for non small-cell lung cancer: a GFPC study.

J. Mazières, G. Quéré, A. Vergnenègre, 2011, Lung cancer.

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

A. Vergnenègre, C. Dubos-Arvis, P. Thomas, 2019, Cancer management and research.

Reply to R.D. Nipp et al, M.-J. Molina-Garrido et al, and A. Gajra et al.

A. Vergnenègre, H. Léna, R. Corre, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

How old is "too old" for translational research?

A. Vergnenègre, H. Léna, R. Corre, 2014, Translational lung cancer research.

Assessment of palliative care for advanced non-small-cell lung cancer in France: a prospective observational multicenter study (GFPC 0804 study).

A. Tchalla, C. Audigier-Valette, A. Vergnenègre, 2013, Lung cancer.

Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.

G. Giaccone, N. Reinmuth, R. Herbst, 2020, The New England journal of medicine.

Cost analysis of erlotinib versus chemotherapy for first-line treatment of non-small-cell lung cancer in frail elderly patients participating in a prospective phase 2 study (GFPC 0505).

C. Chouaid, A. Vergnenègre, R. Corre, 2013, Clinical lung cancer.

Prognostic role of a comprehensive geriatric assessment on the management of elderly patients with advanced non-small cell lung cancer (NSCLC): a pooled analysis of two prospective phase II trials by the GFPC Group.

C. Chouaid, C. Audigier-Valette, A. Vergnenègre, 2017, Journal of thoracic disease.

The cost-effectiveness of paclitaxel (Taxol) + cisplatin is similar to that of teniposide + cisplatin in advanced non-small cell lung cancer: a multicountry analysis.

G. Giaccone, L. Annemans, A. Vergnenègre, 1999, Anti-cancer drugs.

Economic Analysis of First‐Line Treatment with Erlotinib in an EGFR‐Mutated Population with Advanced NSCLC

E. Felip, F. de Marinis, R. Rosell, 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Oral vinorelbine-based concomitant chemoradiotherapy in unresectable stage III non-small cell lung cancer: a systematic review

A. Escande, C. Chouaid, R. Gervais, 2018, Expert review of anticancer therapy.

Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

A. Vergnenègre, A. Jaccard, D. Bordessoule, 2016, Supportive Care in Cancer.

[Interventional radiology and the medical applications of information systems: what consequences for the radiology department?].

M. Druet‐Cabanac, A. Vergnenègre, R. Rymer, 1999, Journal de radiologie.

Comparison between late onset and childhood asthma.

J. Bousquet, A. Vergnenègre, M. Antonini, 1992, Allergologia et immunopathologia.

Abstract CT221: Nivolumab (NIVO) + ipilimumab (IPI) as first-line (1L) treatment for patients with advanced non-small cell lung cancer (NSCLC) with brain metastases: Results from CheckMate 227

K. Syrigos, Keunchil Park, H. Borghaei, 2020 .

[Breast cancer in the early stage].

R. J. Jones, M. Espié, G. Giaccone, 2012, Gan no rinsho. Japan journal of cancer clinics.

Airway obstruction and rheumatoid arthritis.

A. Vergnenègre, M. Antonini, B. Melloni, 1997, The European respiratory journal.

Antioxidant activity in bronchoalveolar lavage fluid from patients with lung cancer.

A. Cantin, A. Vergnenègre, M. Lefebvre, 1996, American journal of respiratory and critical care medicine.

Non-small cell lung cancer, locally advanced

P. Lambin, S. Kozlov, I. Petersen, 2012 .

Association of PALB2 Messenger RNA Expression with Platinum‐Docetaxel Efficacy in Advanced Non–Small Cell Lung Cancer

R. Rosell, J. Ramírez, B. Massuti, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small Cell Lung Cancer: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial.

L. Urban, K. O'Byrne, Keunchil Park, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A. Vergnenègre, M. Antonini, B. Melloni, 1995, Occupational and environmental medicine.

[The costs of asthma in France and the economic implications of its level of control].

B. Detournay, C. Chouaid, A. Vergnenègre, 2011, Revue des maladies respiratoires.

[What is a non-parametric test?].

M. Druet‐Cabanac, P. Preux, A. Vergnenègre, 2003, Revue des maladies respiratoires.

[Prevalence of exercise-induced asthma in school children].

P. Preux, A. Vergnenègre, M. Antonini, 2002, Revue d'epidemiologie et de sante publique.

Sequential versus concurrent chemo-radiation (RT-CT) in locally advanced non small cell lung cancer (NSCLC): A French randomized phase III trial of GLOT-GFPC (NPC 95-01 study)

J. Daurès, P. Souquet, P. Fournel, 2001 .

Nivolumab (NIVO) + low-dose ipilimumab (IPI) vs platinum-doublet chemotherapy (chemo) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): CheckMate 227 part 1 final analysis

K. O'Byrne, S. Ramalingam, M. Hellmann, 2019, Annals of Oncology.

CYTAR: A randomized clinical trial evaluating the preventive effect of doxycycline on erlotinib-induced folliculitis in non-small cell lung cancer patients.

G. Deplanque, C. Robert, O. Chosidow, 2010 .

Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study.

P. Souquet, D. Damotte, C. Chouaid, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[Chronic bronchitis: prevalence and quality of life. Analysis of data from the French Health Interview Survey 2002-2003].

N. Roche, M. Zureik, C. Chouaid, 2009, Revue des maladies respiratoires.

Impact of a comprehensive geriatric assessment to manage elderly patients with locally advanced non-small-cell lung cancers: An open phase II study using concurrent cisplatin-oral vinorelbine and radiotherapy (GFPC 08-06).

R. Descourt, A. Vergnenègre, I. Monnet, 2018, Lung cancer.

Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review

A. Vergnenègre, I. Borget, C. Chouaïd, 2014, ClinicoEconomics and outcomes research : CEOR.

S. Walzer, C. Chouaid, A. Roughley, 2011 .

Randomized follow-up study of resected NSCLC patients: conventional versus 18F-DG coincidence imaging.

J. Monteil, S. Gaillard, A. Vergnenègre, 2010, Anticancer research.

Economic Evaluation of Epilepsy in Kiremba (Burundi): A Case–Control Study

M. Druet‐Cabanac, P. Preux, A. Vergnenègre, 2004, Epilepsia.

[Pneumocystis carinii pneumonia radiologically simulating tuberculosis].

A. Vergnenègre, D. Bordessoule, B. Melloni, 1988, Revue de pneumologie clinique.

[Phase II study of docetaxel in inoperable advanced non small cell lung cancer].

A. Vergnenègre, H. Léna, G. Robinet, 2000, Bulletin du cancer.

An open multicenter phase II trial of docetaxel-gemcitabine in Charlson score and performance status (PS) selected elderly patients with stage IIIB pleura/IV non-small-cell lung cancer (NSCLC): the GFPC 02-02a study.

P. Fournel, C. Chouaid, A. Vergnenègre, 2007, Critical reviews in oncology/hematology.

Targeting the PD-1/PD-L1 Immune Checkpoint in EGFR-Mutated or ALK-Translocated Non-Small-Cell Lung Cancer

F. Guisier, C. Chouaid, R. Gervais, 2017, Targeted Oncology.

ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutation.

F. de Marinis, R. Rosell, B. Massuti, 2014, Translational lung cancer research.

Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).

C. Chouaid, A. Vergnenègre, H. Léna, 2014, Lung cancer.

Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

B. Milleron, M. Taron, G. Zalcman, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Targeted therapies in non-small-cell lung cancer management: no cost-effective strategies?

C. Chouaid, A. Vergnenègre, I. Borget, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Review of economic analyses of treatment for non-small–cell lung cancer (NSCLC)

A. Vergnenègre, C. Chouaïd, 2018, Expert review of pharmacoeconomics & outcomes research.

[Geriatric assessment contribution to treatment decision-making in thoracic oncology].

M. Druet‐Cabanac, T. Dantoine, A. Vergnenègre, 2011, Revue des maladies respiratoires.

Management of elderly patients.

A. Vergnenègre, H. Léna, R. Corre, 2013, Translational lung cancer research.

Nondisruptive p53 Mutations Are Associated with Shorter Survival in Patients with Advanced Non–Small Cell Lung Cancer

R. Rosell, A. Cardona, M. Sánchez-Ronco, 2014, Clinical Cancer Research.

Multicenter randomized trial comparing cisplatin-mitomycin-vinorelbine versus cisplatin-mitomycin-vindesine in advanced non-small cell lung cancer. 'Groupe Français de Pneumo-Cancérologie'.

A. Vergnenègre, J. Guerin, G. Robinet, 1996, Lung cancer.

Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC

H. Ditzel, F. de Marinis, R. Rosell, 2017, Journal of the National Cancer Institute.

Pharmacogenetics in lung cancer for the lay doctor

R. Rosell, M. Taron, B. Massuti, 2008, Targeted Oncology.

Cost analysis of hospital treatment--two chemotherapic regimens for non-surgical non-small cell lung cancer. GFPC (Groupe Français Pneumo Cancérologie)

A. Vergnenègre, M. Pérol, E. Pham, 1996, Lung cancer.

Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)

C. Chouaid, A. Vergnenègre, C. Dubos-Arvis, 2017, Targeted Oncology.

Multicenter phase II trial of nintedanib plus docetaxel in second-line treatment in advanced non-squamous non-small cell lung cancer patients refractory to first-line platin-based chemotherapy (REFRACT GFPC 02-15 study).

F. Guisier, A. Vergnenègre, I. Monnet, 2021, Lung cancer.

Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.

C. Chouaid, R. Gervais, P. Saulnier, 2020, The Lancet. Oncology.

Biomarkers in lung oncology.

R. Rosell, Jia Wei, Baorui Liu, 2010, Pulmonary pharmacology & therapeutics.

Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study

P. Fournel, C. Chouaid, R. Gervais, 2016, Targeted Oncology.

BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

E. Felip, F. de Marinis, J. Bosch-Barrera, 2015, Scientific Reports.

Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study

A. Carrato, M. Thomas, A. Vergnenègre, 2014, Current medical research and opinion.

Real-life effectiveness of erlotinib as second-line treatment of stage IIIB/IV squamous non-small cell lung cancer: Results of the PEPiTA observational study.

N. Girard, O. Molinier, P. Souquet, 2016, Lung cancer.

Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis

P. Fournel, C. Chouaid, A. Vergnenègre, 2007, Current medical research and opinion.

Patients with non-small-cell lung cancer harbouring a BRAF mutation: a multicentre study exploring clinical characteristics, management, and outcomes in a real-life setting: EXPLORE GFPC 02-14.

C. Chouaid, R. Gervais, A. Vergnenègre, 2018, Current oncology.

Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small – Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)

A. Vergnenègre, C. Dubos-Arvis, P. Thomas, 2019 .

Clinical management of molecular alterations identified by high throughput sequencing in patients with advanced solid tumors in treatment failure: Real-world data from a French hospital

F. Thuillier, A. Vergnenègre, E. Deluche, 2023, Frontiers in Oncology.

Induction (ICT) or consolidation chemotherapy (CT) with cisplatin (C) and paclitaxel (P) plus concurrent chemo-radiation (CT/TRT) with cisplatin and vinorelbine (V) for unresectable non-small cell lung cancer (NSCLC) patients (pts): Randomized phase II trial GFPC-GLOT-IFCT 02-01.

P. Souquet, P. Fournel, C. Chouaid, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study.

J. Daurès, P. Souquet, P. Fournel, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Docetaxel and concurrent radiotherapy after two cycles of induction chemotherapy with cisplatin and vinorelbine in patients with locally advanced non-small-cell lung cancer. A phase II trial conducted by the Groupe Francais de Pneumo-Cancerologie (GFPC).

P. Preux, P. Fournel, A. Vergnenègre, 2005, Lung cancer.

Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group.

M. Marty, P. Fournel, A. Vergnenègre, 1995, Anti-cancer drugs.

Cost of Lung Cancer

C. Combescure, B. Housset, J. Daurès, 2012, PharmacoEconomics.

Open-label Phase II trial to evaluate safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination for stage-IV non-small-cell lung cancer - VinMetAtezo trial, (GFPC‡ 04-2017).

A. Vergnenègre, H. Léna, G. Robinet, 2020, Future oncology.

A multicentre phase II randomised trial of weekly docetaxel/gemcitabine followed by erlotinib on progression, vs the reverse sequence, in elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0504 study)

F. Barlesi, C. Chouaid, A. Vergnenègre, 2011, British Journal of Cancer.

Multicenter phase II trial of carboplatin/vinorelbine in elderly patients with advanced non-small-cell lung cancer efficacy and impact on quality of life: Groupe Francais de Pneumo-Cancerologie Study 9902.

P. Auquier, A. Vergnenègre, P. Muller, 2005, Clinical lung cancer.

Second-line therapy with gefitinib in combination with docetaxel for advanced non-small cell lung cancer: a phase II randomized study

F. Barlesi, P. Souquet, P. Fournel, 2007, Targeted Oncology.

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study.

J. Daurès, B. Massuti, R. Descourt, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers

A. Vergnenègre, E. Deluche, R. Veillon, 2019, PloS one.

Oral Vinorelbine and Cisplatin with Concurrent Radiotherapy After Induction Chemotherapy with Cisplatin and Docetaxel for Patients with Locally Advanced Non-small Cell Lung Cancer: The GFPC 05-03 Study

F. Barlesi, P. Fournel, R. Descourt, 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Indoor Radon and Lung Cancer in France

D. Caillaud, D. Laurier, G. Tymen, 2004, Epidemiology.

Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer

P. Fournel, G. Quéré, C. Chouaid, 2019, Targeted Oncology.

Cost of lung cancer: a methodological review.

C. Combescure, B. Housset, J. Daurès, 2006, PharmacoEconomics.

Economics of the clinical management of lung cancer in France: an analysis using a Markov model

C. Combescure, B. Housset, J. Daurès, 2004, British Journal of Cancer.

Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC - IFCT 02-01.

J. Daurès, P. Souquet, P. Fournel, 2016, European journal of cancer.

Cost-minimization analysis of a phase III trial comparing concurrent versus sequential radiochemotherapy for locally advanced non-small-cell lung cancer (GFPC-GLOT 95-01).

C. Combescure, P. Souquet, P. Fournel, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non small cell lung cancer (NSCLC). Interim analysis of toxicity. (GLOT-GFPC NPC 95-01 study)

J. Daurès, P. Souquet, P. Fournel, 2000 .

Cost-Effectiveness Analysis of Individualized Mycophenolate Mofetil Dosing in Kidney Transplant Patients in the APOMYGRE Trial

P. Marquet, G. Hoizey, Y. Le Meur, 2010, Transplantation.

[Indoor radon exposure and lung cancer risk. Results of an epidemiological study carried out in France].

D. Caillaud, D. Laurier, G. Tymen, 2005, Revue des maladies respiratoires.

Economic analyses and lung cancer.

L. Molinier, A. Vergnenègre, C. Chouaïd, 2001, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study

E. Smit, D. Moro-Sibilot, S. Schmitz, 2010, Current medical research and opinion.

Comparison of treatment costs of grade 3/4 adverse events associated with erlotinib or pemetrexed maintenance therapy for patients with advanced non-small-cell lung cancer (NSCLC) in Germany, France, Italy, and Spain.

F. de Marinis, S. Walzer, J. de Castro Carpeno, 2011, Lung cancer.

Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients

L. Thiberville, J. Mazières, D. Moro-Sibilot, 2018, ERJ Open Research.

IMpower110: Interim overall survival (OS) analysis of a phase III study of atezolizumab (atezo) vs platinum-based chemotherapy (chemo) as first-line (1L) treatment (tx) in PD-L1–selected NSCLC

G. Giaccone, N. Reinmuth, R. Herbst, 2019, Annals of Oncology.

Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung cancer after failure of first-line chemotherapy: GFPC 10.02 study.

A. Labrunie, P. Fournel, R. Descourt, 2014, Lung cancer.

Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study

G. Zalcman, P. Fournel, D. Pérol, 2012, BMC Cancer.

Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)

F. Guisier, A. Vergnenègre, P. Dô, 2019, Cancer medicine.

Real-world healthcare resource utilization in a European non-small cell lung cancer population: the EPICLIN-Lung study

A. Carrato, M. Thomas, A. Vergnenègre, 2014, Current medical research and opinion.

Second-line therapy for non-small cell lung cancer in clinical practice: final results and treatment pathways from the SELECTTION observational study

E. Smit, D. Moro-Sibilot, S. Schmitz, 2012, Current medical research and opinion.

Randomized phase III trial of gemcitabine/carboplatin with or without iniparib (BSI-201) in patients with previously untreated stage IV squamous non-small cell lung cancer (NSCLC).

M. Socinski, J. Hainsworth, T. Lynch, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Combinatory effect of BRCA1 and HERC2 expression on outcome in advanced non-small-cell lung cancer

M. Rugge, R. Rosell, M. Taron, 2016, BMC Cancer.

Efficacy of Pemetrexed as Second-Line Therapy in Advanced NSCLC after Either Treatment-Free Interval or Maintenance Therapy with Gemcitabine or Erlotinib in IFCT-GFPC 05-02 Phase III Study

F. Barlesi, P. Fournel, C. Chouaid, 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Two-Stage Bronchoscopic Endobronchial Valve Treatment Can Lead to Progressive Lung Volume Reduction and May Decrease Pneumothorax Risk

A. Vergnenègre, B. Melloni, N. Guibert, 2021, International journal of chronic obstructive pulmonary disease.

Economics of Treatments for Non-Small Cell Lung Cancer

G. Hejblum, C. Chouaid, A. Vergnenègre, 2012, PharmacoEconomics.

Prevention of pollen rhinitis symptoms: comparison of fluticasone propionate aqueous nasal spray and disodium cromoglycate aqueous nasal spray

J. Bousquet, A. Didier, A. Vergnenègre, 1993 .

[Stage IV non-small cell lung cancer. Duration of chemotherapy for locally advanced non small cell lung cancers].

A. Vergnenègre, 2006, Revue des maladies respiratoires.

[Costs, costs and more costs: which one should we use?].

R. Launois, A. Vergnenègre, B. Garrigues, 2003, Bulletin du cancer.

Randomized phase III study of nivolumab and ipilimumab versus carboplatin-based doublet in first-line treatment of PS 2 or elderly (≥ 70 years) patients with advanced non–small cell lung cancer (Energy-GFPC 06-2015 study).

F. Guisier, C. Audigier-Valette, A. Vergnenègre, 2022, Journal of Clinical Oncology.

Author Correction: BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer

E. Felip, F. de Marinis, J. Bosch-Barrera, 2023, Scientific Reports.

Anti PD-1 (nivolumab, pembrolizumab) or anti PD-L1 (atezolizumab) versus docetaxel for previously treated patients with advanced NSCLC: A meta-analysis.

C. Chouaid, A. Vergnenègre, P. Nicolas, 2016 .

The Cost of Lung Cancer Management in France from the Payor’s Perspective

C. Combescure, B. Housset, J. Daurès, 2006 .

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies.

A Vergnenegre, X. Chen, X. Qian, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus “at progression” cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis

R. Gervais, A. Vergnenègre, G. Robinet, 2021, Therapeutic advances in medical oncology.

Integrated genomic analysis by whole exome and transcriptome sequencing of tumor samples from EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with acquired resistance to erlotinib.

J. Weissman, R. Stahel, A. Uzilov, 2013 .

Phase II randomized multicenter study evaluating a treatment regimen alternating docetaxel and cisplatin-vinorelbine with a cisplatin-vinorelbine control group in patients with stage IV non-small-cell lung cancer: GFPC 97.01 study.

J. Vernejoux, P. Fournel, C. Belleguic, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[French translation and validation of the Edinburgh Questionnaire for the diagnosis of intermittent claudication].

V. Aboyans, A. Vergnenègre, M. Laskar, 2000, Archives des maladies du coeur et des vaisseaux.

O81 IMpower110: interim overall survival (OS) analysis of a phase III study of atezolizumab (ATEZO) monotherapy vs platinum-based chemotherapy (CHEMO) as first-line (1L) treatment in PD-L1–selected NSCLC

G. Giaccone, N. Reinmuth, R. Herbst, 2020, Journal of Immunotherapy for Cancer.

A Randomized Phase II Trial Assessing in Advanced Non-small Cell Lung Cancer Patients with Stable Disease after Two Courses of Cisplatin-Gemcitabine an Early Modification of Chemotherapy Doublet with Paclitaxel-Gemcitabine Versus Continuation of Cisplatin-Gemcitabine Chemotherapy (GFPC 03-01 Study)

J. Vernejoux, F. Barlesi, P. Fournel, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Safety and efficacy of second-line metronomic oral vinorelbine-atezolizumab combination in stage IV non-small-cell lung cancer: An open-label phase II trial (VinMetAtezo).

F. Guisier, A. Vergnenègre, R. Corre, 2023, Lung cancer.

Economic impact of second- and third-line erlotinib treatment of non small-cell lung cancer: a French observational study: P1-245

C. Chouaid, A. Vergnenègre, C. Coudray-Omnès, 2007, Revue des maladies respiratoires.

Simulation and comparison of progression-free survival among patients with non-squamous non-small-cell lung cancer receiving sequential therapy

F. de Marinis, D. Gultyaev, S. Walzer, 2015, Expert review of anticancer therapy.

Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC).

E. Mueller, S. Walzer, C. Chouaid, 2010, Lung cancer.

Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer

S. Walzer, J. Ray, C. Chouaid, 2012, ClinicoEconomics and outcomes research : CEOR.

Randomised, multicentre phase II study assessing two doses of docetaxel (75 or 100 mg/m2) as second-line monotherapy for non-small-cell lung cancer.

E. Lemarié, B. Milleron, J. Pujol, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Interim analysis of the Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized therapy in advanced non-small cell lung cancer (NSCLC) patients (p) (NCT00617656/GECP-BREC).

R. Rosell, M. Sánchez-Ronco, M. Provencio, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

OA15.02 Carboplatin-Etoposide Versus Topotecan as Second-Line Treatment for Sensitive Relapsed Small-Cell Lung Cancer: Phase 3 Trial

R. Gervais, P. Saulnier, A. Vergnenègre, 2019, Journal of Thoracic Oncology.

OA10.03 YAP-NOTCH and STAT3 Signaling Rebound as a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer

R. Rosell, A. Cardona, P. Ma, 2017 .

E. Felip, F. de Marinis, G. Altavilla, 2012, The Lancet. Oncology.

Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents

C. Chouaid, A. Vergnenègre, I. Borget, 2013, ClinicoEconomics and outcomes research : CEOR.

Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe

S. Walzer, M. Tiseo, J. Ray, 2012, ClinicoEconomics and outcomes research : CEOR.

A cross-market cost comparison of erlotinib versus pemetrexed for first-line maintenance treatment of patients with locally advanced or metastatic non-small-cell lung cancer.

S. Walzer, C. Chouaid, D. Heigener, 2012, Lung cancer.